Who We Are
Wellmarker Bio Co., Ltd.(WMBIO) Develops Anticancer Drugs Based on Predictive Biomarkers for Unmet Medical Needs
Wellmarker Bio is a spin-off company from Seoul Asan Medical Center (AMC), which is the largest and most renowned hospital in the Republic of Korea. We specialize in developing predictive biomarkers and first-in-class drugs through profound research know-hows and clinical information from AMC. We strive to bring a better outcome to patients and contribute to the healthy life of a mankind through ‘Research Institute’ that is comprised of Target discovery department, Drug discovery department, Medicinal chemistry department, and CMC department.
Areas of Expertise
We are developing predictive biomarkers and anticancer drugs for solid tumors by utilizing in-house research facilities and clinical information from AMC.
On many occasions, “new drug development” can be said to be a “comprehensive art.” To perform this “comprehensive art”, it requires an amazing storyline, stage setting, and above all, a great actor. In the same way, WMBIO continues to make ceaseless effort on developing new drugs by working together with global partners. We will continue to strive in contributing to the healthy life of mankind.
Company History
-
- 2016.
-
12Company Founded
-
- 2017.
-
04R&D Center Established
05Pipeline WM-S1(Small Molecule, Colon Cancer)
Has Been Selected by KDDF* KDDF: Korea Drug Development Fund06Startup R&D Support Program Selected by MSS* MSS: Ministry of SMEs and Startups
07Acquired the Venture Business Certification
10Research Collaboration Agreement with Y-Biologics
-
- 2018.
-
02Pipeline WM-A1(Therapeutic Antibody, Lung Cancer) Has Been Selected by KDDF
07WM-S1 Poster Presentation at AACR Annual Meeting* AACR: American Association for Cancer Research
07WM-A1 Poster Presentation at AACR Annual Meeting
10Completed Series A($28million)
11Startup R&D Support Program Selected by MSS [Academy]
11Company Presentation at the 5th BioCentury China Healthcare Summit
-
- 2019.
-
02MOU Signed with KIRAMS(Korea Institute for Radiological and Medical Sciences)
03MOU Signed with Ukrainian National Medical Institutions (VNMU/PRCO)
03Pipeline WM-S1 Has Been Selected as a KDDF Follow-up Project
06MOU Signed with Cytogen for Companion Diagnostics
07Signed Technology Transfer Contract with KIRAMS(L/I)
07Completed Series B($18million)
10MOU Signed with Azothbio
10Received the Grand Prize at the ‘2019 5th Korean Good Company Awards’ in Bio Sector
-
- 2020.
-
03Research Collaboration Agreement with AzothBio on AI-based Anticancer Drug Development
05Branch Research Center(CMC Center) Established
05Startup R&D Support Program Selected by MSS [Technology Commercialization]
05WM-S1 Poster Presentation at ASCO Annual Meeting (with Cytogen)*ASCO: American Society of Clinical Oncology
10Received the Grand Prize at the ‘2020 6thKorean Good Company Awards’ in Bio Sector for 2 Consecutive Years
12WM-S1 Phase I Clinical Trial Submission(Australian TGA)* TGA: Therapeutic Goods Administration
-
- 2021.
-
02WM-S1 Phase I Clinical Trial Approval(TGA)
04WM-A1 Poster Presentation at AACR Annual Meeting
06R&D Center Designated as an 'Excellent Corporation R&D Center' by the Ministry of Science and ICT of Korea
08Completed Series C($14million)
09WMBIO receives Innobiz(Innovation + Business) certification from the Ministry of SMEs
-
- 2022.
-
01Research Collaboration Agreement with Isogenica
03WM-S1 Phase I Clinical Trial Approval(Korea MFDS)
03WMBIO acquires "Certification of Excellence in Employee Invention Promotion"
04WM-S1(Solid Tumors & Combo) Poster Presentation at AACR Annual Meeting
04MOU Signed with Inje University Paik Hospital
04WM-A1 Selected by KDDF(Follow-up Project)
04MOU Signed with Isogenica
05WMBIO acquires "Certificate of IP Management Enterprise"
06Licensing and Research Collaboration Agreement with Oncozen Biotech
Organizational Structure
Collaborations
Wellmarker Bio is Committed to Developing New Drugs through
Continuous Cooperation with Global Partners
